Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes

被引:0
作者
Yundeok Kim
In-Ho Kim
Hyeong Joon Kim
Silvia Park
Kyoo-Hyung Lee
Soo Jeong Kim
Jung-Hee Lee
Dae-Young Kim
Sung-Soo Yoon
Yeo-Keoung Kim
Jun Ho Jang
Seon Yang Park
Jae-Sook Ahn
Chul Won Cheong
Je-Hwan Lee
June-Won Cheong
机构
[1] Yonsei University College of Medicine,Severance Hospital
[2] Seoul National University Hospital,Samsung Medical Center
[3] Chonnam National University Hwasun Hospital,Asan Medical Center
[4] Sungkyunkwan University School of Medicine,undefined
[5] University of Ulsan College of Medicine,undefined
来源
International Journal of Hematology | 2014年 / 99卷
关键词
Myelodysplastic syndrome; Hypomethylating agent; AlloSCT;
D O I
暂无
中图分类号
学科分类号
摘要
Allogeneic hematopoietic stem cell transplantation (alloSCT) is currently the only curative treatment modality for myelodysplastic syndromes (MDS). The treatment paradigm for MDS has changed in recent years with the introduction of hypomethylating agents (HMAs). The present retrospective multicenter study was designed to assess the effects of pre-transplant HMA on transplant outcome and determine which patients would benefit most from this therapy. A total of 109 patients who received alloSCT at one of five institutions between 2007 and 2010 were enrolled in this study regardless of pre-transplant HMA therapy. 81 of the 109 patients enrolled were treated with HMA prior to alloSCT. 28 patients received alloSCT without HMA bridging. The distributions of WHO classification groups and IPSS scores were similar between the two groups (P = 0.752 and P = 0.265, respectively). Pre-transplant HMA did not affect OS (P = 0.244), and there were no differences in response to HMA therapy within the HMA-treated group. The cumulative incidence of NRM was not significantly different between the two groups (P = 0.500). However, for patients with a high blast count (>5 % of bone marrow at the time of diagnosis), pre-transplant HMA therapy had a NRM benefit (83.3 vs. 48.6 %, P = 0.014).
引用
收藏
页码:635 / 643
页数:8
相关论文
共 50 条
  • [41] Hematopoietic Stem Cell Transplantation in the Management of Myelodysplastic Syndrome: A Retrospective, Current, and Future Perspective
    Qimudesiren
    Yin, Wenjie
    Wang, Yuhong
    Qing, Guo
    Bao, Jinhua
    Chaomurilige
    Chen, Shana
    Qian, Liren
    CELL TRANSPLANTATION, 2024, 33
  • [42] Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies
    Guieze, Romain
    Damaj, Gandhi
    Pereira, Bruno
    Robin, Marie
    Chevallier, Patrice
    Michallet, Mauricette
    Vigouroux, Stephane
    Beguin, Yves
    Blaise, Didier
    El Cheikh, Jean
    Roos-Weil, Damien
    Thiebaut, Anne
    Rohrlich, Pierre-Simon
    Huynh, Anne
    Cornillon, Jerome
    Contentin, Nathalie
    Suarez, Felipe
    Lioure, Bruno
    Mohty, Mohamad
    Maillard, Natacha
    Clement, Laurence
    Francois, Sylvie
    Guillerm, Gaelle
    Yakoub-Agha, Ibrahim
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (02) : 240 - 247
  • [43] Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study
    B Strahm
    P Nöllke
    M Zecca
    E T Korthof
    M Bierings
    I Furlan
    P Sedlacek
    A Chybicka
    M Schmugge
    V Bordon
    C Peters
    A O'Marcaigh
    C D de Heredia
    E Bergstraesser
    B D Moerloose
    M M van den Heuvel-Eibrink
    J Starý
    M Trebo
    D Wojcik
    C M Niemeyer
    F Locatelli
    Leukemia, 2011, 25 : 455 - 462
  • [44] Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study
    Strahm, B.
    Noellke, P.
    Zecca, M.
    Korthof, E. T.
    Bierings, M.
    Furlan, I.
    Sedlacek, P.
    Chybicka, A.
    Schmugge, M.
    Bordon, V.
    Peters, C.
    O'Marcaigh, A.
    de Heredia, C. D.
    Bergstraesser, E.
    Moerloose, B. D.
    van den Heuvel-Eibrink, M. M.
    Stary, J.
    Trebo, M.
    Wojcik, D.
    Niemeyer, C. M.
    Locatelli, F.
    LEUKEMIA, 2011, 25 (03) : 455 - 462
  • [45] Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes
    P Armand
    H J Deeg
    H T Kim
    H Lee
    P Armistead
    M de Lima
    V Gupta
    R J Soiffer
    Bone Marrow Transplantation, 2010, 45 : 877 - 885
  • [46] Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes
    Armand, P.
    Deeg, H. J.
    Kim, H. T.
    Lee, H.
    Armistead, P.
    de Lima, M.
    Gupta, V.
    Soiffer, R. J.
    BONE MARROW TRANSPLANTATION, 2010, 45 (05) : 877 - 885
  • [47] Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD
    Vilorio-Marques, Laura
    Fernandez, Christelle Castanon
    Mora, Elvira
    Gutierrez, Lorena
    Bua, Beatriz Rey
    Lorenzo, Maria Jose Jimenez
    Beya, Marina Diaz
    Pampliega, Miriam Vara
    Molero, Antonieta
    Sanchez-Garcia, Joaquin
    Calabuig, Marisa
    Cedena, Maria Teresa
    Chen-Liang, Tzu
    Santa, Johana Alejandra Diaz
    Padilla, Irene
    Hernandez, Francisca
    Diez, Rosana
    Asensi, Pedro
    Xicoy, Blanca
    Sanz, Guillermo
    Valcarcel, David
    Diez-Campelo, Maria
    Bernal, Teresa
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [48] Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes
    Yanada, Masamitsu
    Mizuno, Shohei
    Yamasaki, Satoshi
    Harada, Kaito
    Konuma, Takaaki
    Tamaki, Hiroya
    Shingai, Naoki
    Uchida, Naoyuki
    Ozawa, Yukiyasu
    Tanaka, Masatsugu
    Onizuka, Makoto
    Sawa, Masashi
    Nakamae, Hirohisa
    Shiratori, Souichi
    Matsuoka, Ken-ichi
    Eto, Tetsuya
    Kawakita, Toshiro
    Maruyama, Yumiko
    Ichinohe, Tatsuo
    Kanda, Yoshinobu
    Atsuta, Yoshiko
    Aoki, Jun
    Yano, Shingo
    LEUKEMIA & LYMPHOMA, 2021, 62 (14) : 3411 - 3419
  • [49] Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature
    Im, Annie
    Raptis, Anastasios
    Hou, Jing-Zhou
    Tompkins, Cheryl
    Winfield, Melissa
    Guay, Mary
    Boyiadzis, Michael
    Agha, Mounzer
    ACTA HAEMATOLOGICA, 2016, 135 (04) : 232 - 237
  • [50] One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant
    Bewersdorf, Jan Philipp
    Stahl, Maximilian
    Zeidan, Amer M.
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (08) : 575 - 578